Phastar

An announcement made by Phastar regarding entry into Medidata’s platform & additional global offices

Global expansion is going to take place by Phastar as it will be adding offices in the West Coast of the United States, as well as, in Tokyo, Japan. In addition to this, it will be tapping into an association with to use clinical data solutions as its operations expand.
The firm, which provides data management, statistical consulting, clinical trial reporting, and data science services, said that the addition of these new offices is part of its current 5-year plan for development to both its talent pools & access global biotechnological hubs.
Phastar has already offices all across Europe, Kenya, Australia, and the East Coast of the United States, but the Chief Executive Officer of the firm ‘Kevin Kane’ said that opening offices on the West Coast of the United States & Japan will provide the company with better access to clinical study design and reporting experts.
According to the CEO, the office in Japan will enable the firm to have better access to the domestic pharma & biotech market. The locations were also selected as they are near the existing customers, and the senior staff at the new location will be able to carry on the enhancement in the company’s customer interface.
Kane stated that the firm is already 18 months into the plan and saw a year one full-time employee headcount growth of 34 percent. In terms of statistical CRO groups, our rival intelligence lists us as the 10th largest team internationally. We have a goal to become one of the top-five by the end of the 5-year plan.”
He further said that the company envision to double the revenue over the 5-year period and are well on target, with a 36 percent growth in the first year and an anticipated growth of around 30 percent for the next year. If this increases, the firm will deliver the five-year plan in a shorter span of time.
Kanye told that the firm is facing new challenges in spite of the growth and is taking steps to reduce the associated risks.

, , , , , ,